| 1. |
Migraine management in special populations |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Plans to speed up the approval of copycat versions of HIV and AIDS drugs have been announced by the US government |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Influenza vaccination levels are low among adults with asthma in the US, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Donepezil enhances cognitive function, QOL in AD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Alzheimer's disease (AD) is a disorder characterised by a progressive deterioration of physical and mental function, which can significantly reduce patients' autonomy and QOL. AD is the most common cause of dementia in the elderly, and elderly AD patients require costly specialised chronic supportive and therapeutic care. As such, AD is one of the most costly diseases in the Western world. The benefits of successful drug therapy in AD include a reduction in caregiver hours, improved QOL for both patients and caregivers, and considerable cost savings. Donepezil, a selective acetylcholinesterase inhibitor, can improve cognitive functioning and QOL among patients with mild to moderately-severe AD, according to the results of a study presented at the 157th Annual Meeting of the American Psychiatric Association (APA) [New York, US; May 2004]. Another study presented at the meeting showed that persistence with donepezil therapy enhances cognitive, functional and behavioural outcomes among such patients, and can lead to reduced labour costs.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Clopidogrel a cost-effective addition to standard ACS therapy in Sweden |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Opioid analgesic prescribing highly variable |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Human skin replacement*is of benefit in patients with hard-to-heal venous leg ulcers, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Rofecoxib vs dexketoprofen trometamol for dental pain |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Antibacterial desensitisation for allergic patients"safe and useful" |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Paroxetine controlled-release: benefits in fibromyalgia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1438,
2004,
Page 11-12
RM Poole,
Preview
|
|
摘要:
The selective serotonin reuptake inhibitor (SSRI) paroxetine provides benefits for patients with fibromyalgia, according to a study presented at the 157th Annual Meeting of the American Psychiatric Association [New York, US; May 2004]. In this placebo-controlled study, treatment with controlled-release paroxetine was well tolerated and produced improvements from baseline in fibromyalgia symptoms in a significantly greater proportion of patients, compared with placebo.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
